alanyl-glutamine + Clinisol

This investigational nutritional pharmacotherapy consists of the stable dipeptide **L-alanyl-L-glutamine** (marketed as **Dipeptiven**) added to a standard 15% amino acid solution (**Clinisol**). Developed for use in critically ill surgical ICU patients, particularly those recovering from major cardiac, vascular, or colonic surgeries, the therapy is designed to address the relative glutamine deficiency that occurs during critical illness. By providing 0.5 g/kg/day of the glutamine dipeptide, the treatment aims to restore plasma glutamine levels, which in turn up-regulates cytoprotective molecules such as **glutathione** and **heat shock proteins** (e.g., HSP-70 and HSP-27). These mechanisms are thought to improve epithelial barrier defenses and immune cell function, thereby reducing the incidence of nosocomial infections and improving overall clinical outcomes. The therapy has been evaluated in Phase III clinical trials led by researchers at **Emory University**.

Brand names

DipeptivenClinisol

Other names

L-alanyl-L-glutamine + 15% ClinisolGlutamine dipeptide-supplemented parenteral nutritionglutamine dipeptide + Clinisol-Emory University-critical illness